Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy

被引：64
作者：
Riihijarvi, Sari [1 ,2 ]
Taskinen, Minna [1 ,2 ]
Jerkeman, Mats [3 ]
Leppa, Sirpa [1 ,2 ]
机构：
[1] Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland
[2] Univ Helsinki, Biomedicum Helsinki, Genome Scale Biol Res Program, FIN-00029 Helsinki, Finland
[3] Lund Univ, Dept Oncol, Lund, Sweden
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2011年 / 86卷 / 02期
关键词：
B-cell non-Hodgkin lymphoma; prognostic factors; gender; immunochemotherapy; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; FOLLICULAR LYMPHOMA; ELDERLY-PATIENTS; CHOP;
D O I：
10.1111/j.1600-0609.2010.01541.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Male gender is an adverse prognostic factor in Hodgkin's lymphoma, but no such association has yet been established in non-Hodgkin lymphomas. Here, we have evaluated whether gender has prognostic impact on the survival of patients with B-cell non-Hodgkin lymphoma in the postrituximab era of lymphoma therapies. The study populations consisted of 217 diffuse large B-cell lymphoma (DLBCL) and 110 follicular lymphoma (FL) patients treated with immunochemotherapy. Hundred and sixty chemotherapy-treated DLBCL patients served as a control group. According to Kaplan-Meier analyses, female patients had a significantly better progression-free survival than men both in DLBCL (4 yr PFS 75% vs. 60%; P = 0.013) and in FL (4 yr PFS 68% vs. 52%, P = 0.036) patients treated with immunochemotherapy. In chemotherapy-treated DLBCL patients, no difference in survival between the genders was found. The results support the idea that women seem to respond better to rituximab.
引用
收藏
页码：124 / 128
页数：5
相关论文
共 12 条
  • [1] Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma
    Cho, Hyun-Jung
    Eom, Hyeon-Seok
    Kim, Hyun-Ju
    Kim, In-Suk
    Lee, Gyeong Won
    Kong, Sun-Young
    [J]. CANCER GENETICS AND CYTOGENETICS, 2010, 198 (01) : 40 - 46
  • [2] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [3] Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    Habermann, Thomas M.
    Weller, Edie A.
    Morrison, Vicki A.
    Gascoyne, Randy D.
    Cassileth, Peter A.
    Cohn, Jeffrey B.
    Dakhil, Shaker R.
    Woda, Bruce
    Fisher, Richard I.
    Peterson, Bruce A.
    Horning, Sandra J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3121 - 3127
  • [4] Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma:: An East German Study Group hematology and oncology study
    Herold, Michael
    Haas, Antje
    Srock, Stefanie
    Neser, Sabine
    Al-Ali, Kathrin Haifa
    Neubauer, Andreas
    Doelken, Gottfried
    Naumann, Ralph
    Knauf, Wolfgang
    Freund, Mathias
    Rohrberg, Robert
    Hoeffken, Klaus
    Franke, Astrid
    Ittel, Thomas
    Kettner, Erika
    Haak, Ursula
    Mey, Ulrich
    Klinkenstein, Christian
    Assmann, Michael
    von Gruenhagen, Ullrich
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 1986 - 1992
  • [5] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    Hiddemann, W
    Kneba, M
    Dreyling, M
    Schmitz, N
    Lengfelder, E
    Schmits, R
    Reiser, M
    Metzner, B
    Harder, H
    Hegewisch-Becker, S
    Fischer, T
    Kropff, M
    Reis, HE
    Freund, M
    Wörmann, B
    Fuchs, R
    Planker, M
    Schimke, J
    Eimermacher, H
    Trümper, L
    Aldaoud, A
    Parwaresch, R
    Unterhalt, M
    [J]. BLOOD, 2005, 106 (12) : 3725 - 3732
  • [6] CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    Marcus, R
    Imrie, K
    Belch, A
    Cunningham, D
    Flores, E
    Catalano, J
    Solal-Celigny, P
    Offner, F
    Walewski, J
    Raposo, J
    Jack, A
    Smith, P
    [J]. BLOOD, 2005, 105 (04) : 1417 - 1423
  • [7] Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab
    Ngo, Lynette
    Hee, Siew-Wan
    Lim, Lay-Cheng
    Tao, Miriam
    Quek, Richard
    Yap, Swee-Peng
    Loong, Er-Li
    Sng, Ivy
    Hwan-Cheong, Tan Leonard
    Ang, Mei-Kim
    Ngeow, Joanne
    Tham, Chee-Kian
    Tan, Min-Han
    Lim, Soon-Thye
    [J]. LEUKEMIA & LYMPHOMA, 2008, 49 (03) : 462 - 469
  • [8] Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
    Pfreundschuh, Michael
    Schubert, Joerg
    Ziepert, Marita
    Schmits, Rudolf
    Mohren, Martin
    Lengfelder, Eva
    Reiser, Marcel
    Nickenig, Christina
    Clemens, Michael
    Peter, Norma
    Bokemeyer, Carsten
    Eimermacher, Hartmut
    Ho, Anthony
    Hoffmann, Martin
    Mertelsmann, Roland
    Truemper, Lorenz
    Balleisen, Leopold
    Liersch, Ruediger
    Metzner, Bernd
    Hartmann, Frank
    Glass, Bertram
    Poeschel, Viola
    Schmitz, Norbert
    Ruebe, Christian
    Feller, Alfred C.
    Loeffler, Markus
    [J]. LANCET ONCOLOGY, 2008, 9 (02) : 105 - 116
  • [9] Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results From 4 Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL).
    Pfreundschuh, Michael
    Murawski, Niels
    Zeynalova, Samira
    Poeschel, Viola
    Reiser, Marcel
    Ho, Anthony D.
    Nickenig, Christina
    Wessendorf, Swen
    Metzner, Bernd
    Grass, Sandra
    Schubert, Joerg
    Loeffler, Markus
    Schmitz, Norbert
    [J]. BLOOD, 2009, 114 (22) : 1431 - 1431
  • [10] CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Pfreundschuh, Michael
    Trumper, Lorenz
    Osterborg, Anders
    Pettengell, Ruth
    Trneny, Marek
    Imrie, Kevin
    Ma, David
    Gill, Devinder
    Walewski, Jan
    Zinzani, Pier-Luigi
    Stahel, Rolf
    Kvaloy, Stein
    Shpilberg, Ofer
    Jaeger, Ulrich
    Hansen, Mads
    Lehtinen, Tuula
    Lopez-Guillermo, Armando
    Corrado, Claudia
    Scheliga, Adriana
    Milpied, Noel
    Mendila, Myriam
    Rashford, Michelle
    Kuhnt, Evelyn
    Loeffler, Markus
    [J]. LANCET ONCOLOGY, 2006, 7 (05) : 379 - 391
12